NetworkNewsBreaks – Zenosense, Inc. (ZENO) Trans

NetworkNewsBreaks – Zenosense, Inc. (ZENO) Transforming Modern Cardiac Diagnostics

Zenosense (OTC: ZENO), through the development of MIDS Cardiac™, seeks to provide a technology that delivers laboratory-level accuracy at the point of care. An article discussing the company’s recent success reads: “A successful development of MIDS Cardiac is just the first step in the development of a wider technology platform that could be adapted to a wide range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense and MIDS Medical Limited are planning to use the platform to develop a multi-capability, highly sensitive point of care device that could test for numerous conditions, including prostate, colorectal and other cancers, inflammatory and autoimmune disease, osteoporosis, endocrine ailments, blood infections, respiratory viruses, meningitis, rheumatism, hepatitis, HIV, chlamydia and many more.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer